Chimeric Antigen Receptor-Natural Killer Cells: The Future of Cancer Immunotherapy

REFERENCES

1. 1.↵
   1. Chen Y,
   2. Liu D

   . Chimeric antigen receptor (CAR)-directed adoptive immunotherapy: a new era in targeted cancer therapy. Stem Cell Investig. 2014 Jan 18;1:2. doi: 10.3978/j.issn.2306-9759.2013.12.01.

   OpenUrlCrossRef
2. 2.↵
   1. Kalaitsidou M,
   2. Kueberuwa G,
   3. Schütt A,
   4. Gilham DE

   . CAR T-cell therapy: toxicity and the relevance of preclinical models. Immunotherapy. 2015;7(5):487-497. doi: 10.2217/imt.14.123.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Holdenrieder S,
   2. Eichhorn P,
   3. Beuers U,
   4. et al.

   Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism. Anticancer Res. 2007 Jul-Aug;27(4A):2041-2045.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Glienke W,
   2. Esser R,
   3. Priesner C,
   4. et al.

   Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol. 2015 Feb 12;6:21. doi: 10.3389/fphar.2015.00021.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Bollino D,
   2. Webb TJ.

   Chimeric antigen receptor–engineered natural killer and natural killer T cells for cancer immunotherapy. Transl Res. 2017 Sep;187:32-43. doi: 10.1016/j.trsl.2017.06.003.

   OpenUrlCrossRef
6. 6.↵
   1. Grossenbacher SK,
   2. Aguilar EG,
   3. Murphy WJ

   . Leveraging natural killer cells for cancer immunotherapy. Immunotherapy. 2017 May;9(6):487-497. doi: 10.2217/imt-2017-0013.

   OpenUrlCrossRef
7. 7.↵
   1. Schuster SJ,
   2. Svoboda J,
   3. Chong EA,
   4. et al.

   Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566.

   OpenUrlCrossRefPubMed